LANDMARK PAPER DEFINING CROHN’S DISEASE (1932)2018-10-15 15:49:50
Eighty-six years ago today, Burrill B. Crohn, Leon Ginzburg, and Gordon D. Oppenheimer published a paper titled Regional Ileitis – A Pathologic and Clinical Entity in the Journal of the American Medical Association (vol. 99, no. 16, pp 1323-1329, October 15, 1932). Honoring the importance of this report, the article was later reprinted as a Landmark Article in The Mount Sinai Journal of Medicine (vol 67, no. 3, pp 263-268, May 2006). We provide the original JAMA article here for users interested in reading this influential publication in its original form. Note: the reprinted version in the Mount Sinai Journal of Medicine has better print quality. The picture of B.B. Crohn is credited to Wikipedia.
Comment: I appreciate history as I grow older. Also, it is important to read original published reports to avoid misquoting or perpetuating misunderstandings. Interesting note: As described in Wikipedia, Crohn always preferred the medically descriptive terms "regional ileitis" and "regional enteritis" to "Crohn's disease", but he was not able to prevent the appropriation of his name for the disease.
Without providing much detail, B.B. Crohn’s article mentions efforts to determine if Mycobacterium tuberculosis was involved in the regional ileitis cases he described including culture for M. tuberculosis, inoculation of lymph node homogenates from five patients into guinea pigs, rabbits, and chickens, and acid-fast staining of tissue sections. He concludes that M. tuberculosis was not a cause of these cases of regional ileitis. However, he never mentions the 1913 report by Dalziel or makes any mention of Mycobacterium paratuberculosis or the similarities of regional ileitis in humans to that of cattle, as described by H.A. Johne in 1895. How might history be different had Dr. Crohn mentioned the possibility of M. a. paratuberculosis (MAP)?
MAP & CROHN'S & REDHILL BIOPHARMA - MORE DETAILS.2018-08-27 14:04:40
Primary endpoint successfully achieved - superior remission rate at week 26 in patients treated with RHB-104 (p= 0.013).
Key secondary endpoints also met, demonstrating consistent benefit to Crohn’s disease patients treated with RHB-104.
Comment: The real proof is in the final peer reviewed publication: Repeating comments from the prior new item, if the final published results of this trial are consistent with the claims in this press release, it represents a final piece of evidence indicating that MAP is a cause of Crohn’s disease. This would heighten the need for veterinary medicine, animal agriculture, and relevant governmental agencies concerned with food safety to limit contamination of food and water by MAP.
Welcome to the updated and improved johnes.org!!
Thanks to the support from our generous sponsors, our website has a fresh look, more images, and 100% edited and updated content. We give special thanks to our platinum sponsors, Zoetis and encourage you to follow links to their home pages.
If you are on our e-list, you will continue to receive notification of updates and news items. If you wish your name to be added to our e-list, click the "subscribe" button in the footer.
« Previous 1 … 8 9 10